FDA-approved
Skin & aging
Icatibant
Evidence
FDA approved
Class
Bradykinin B2 receptor antagonist
KEY TAKEAWAY
Icatibant is a synthetic ten-amino-acid peptide that resembles bradykinin. It is sold as Firazyr and as generics. The FDA approved icatibant (Firazyr) in 2011 for acute attacks of hereditary angioedema in adults, and later for younger patients.
Written by the Veylo editorial team · Updated
November 2026
What it is
Bradykinin B2 receptor antagonist
Approved for
Acute attacks of hereditary angioedema
Key fact
The FDA approved icatibant (Firazyr) in 2011 for acute attacks of hereditary angioedema in adults, and later for younger patients.
Route
Subcutaneous injection that patients can learn to give themselves
Evidence strength
FDA approved
Icatibant is a synthetic ten-amino-acid peptide that resembles bradykinin. It is sold as Firazyr and as generics.
It blocks the bradykinin B2 receptor, which prevents the swelling and pain of hereditary angioedema attacks.
The FDA approved icatibant (Firazyr) in 2011 for acute attacks of hereditary angioedema in adults, and later for younger patients.
Acute attacks of hereditary angioedema.
Redness, swelling and pain at the injection site are very common. Dizziness and fever can occur.
U.S. FDA prescribing information for Icatibant. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.